Saudi Arabia Pharmaceuticals market report gives a comprehensive outlook of Saudi Arabia pharmaceuticals across the value chain with special emphasis on market size analysis of different drugs in various diseases. This report on Saudi Arabia pharmaceuticals market gives historical, current, and future market sizes (US$ Mn) of product types, diseases, and distribution channels in the country. The report studies Saudi Arabia pharmaceuticals market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, Saudi Arabia pharmaceuticals market report covers the regulatory overview, pricing analysis, and reimbursement scenario, healthcare indicators along with newer product introductions, company share analysis, brand share analysis of drug classes, and competition analysis with vividly illustrated competition dashboard to assess the market competition. A sample of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/saudi-arabia-pharmaceuticals-market/#ulp-4H8Z4LpNMLEuOnnx[/URL]
The Saudi Arabia Pharmaceuticals market estimated to be valued US$ 5,748 Mn in 2017 and poised to grow at CAGR 6.7%. The market for Saudi Arabia Pharmaceuticals projected to reach US$ 8,465 Mn by 2023.
Rising prevalence of various chronic diseases such as diabetes, ischemic heart disease, stroke, obesity, hypertension, cancer among Saudi nationals is creating market demand pharmaceuticals in the country. Drug treating chronic ailments are expected to provide lucrative market opportunities for the players in the country. Moreover, these chronic diseases are a major cause of death in Saudi Arabia. According to World Health Organization (WHO) – Noncommunicable Diseases (NCD) Country Profiles, 2014 data, NCDs are estimated to account 78% of total deaths and among NCDs cardiovascular diseases accounted for 46% of total deaths.
Growing local government’s commitment to providing quality healthcare to Saudis and non-Saudis and mandatory health insurance for expatriates working in private sector expected to boost Saudi Arabia pharmaceuticals market over the forecast period. Moreover, healthcare reforms like 100% FDI in Pharma sector expected to create ample growth opportunities for multinational players in the country. Moreover, in 2015, Government of Saudi Arabia allocated around US$ 43 Bn for healthcare sector to build three new hospitals, three blood banks, 11 medical centers, 10 comprehensive care clinics and numerous primary care centers across the country.
To view TOC of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/saudi-arabia-pharmaceuticals-market/#ulp-c654SbFYO64MsOhu[/URL]
Competition Assessment
Key players profiled in the Saudi Arabia pharmaceuticals market include:
• GlaxoSmithKline Plc. (UK)
• Jamjoom Pharma (Saudi Arabia)
• Juphar (UAE)
• Novartis AG (Switzerland)
• Pfizer Inc. (US)
• Riyadh Pharma (Saudi Arabia)
• Sanofi (France)
• SPIMACO (Saudi Arabia)
• Tabuk Pharmaceuticals Manufacturing Co. (Saudi Arabia)
Need more information about this report @
[URL]https://www.precisionbusinessinsights.com/market-reports/saudi-arabia-pharmaceuticals-market/#ulp-14mlyhjMGhVjZqa3[/URL]